Literature DB >> 21132004

Well-differentiated neuroendocrine tumors: a review covering basic principles to loco-regional and targeted therapies.

C Schmidt1, M Bloomston, M H Shah.   

Abstract

Neuroendocrine tumors (NETs) are a complex group of malignancies with variable prognosis and response to treatment. For pancreatic neuroendocrine and carcinoid tumors, traditional cytotoxic chemotherapies have demonstrated minimal activity. Current approaches for treatment of metastatic disease use a combination of loco-regional and targeted biological therapies. Clinical trials remain critical for evaluation of new and promising therapeutic options for patients with NETs.

Entities:  

Mesh：

Substances：

Year:  2010        PMID： 21132004      PMCID： PMC4080204          DOI： 10.1038/onc.2010.548

Source DB:  PubMed          Journal:  Oncogene        ISSN： 0950-9232            Impact factor:   9.867


  52 in total

1.  A Phase II study of high-dose paclitaxel in patients with advanced neuroendocrine tumors.

Authors:  S M Ansell; H C Pitot; P A Burch; L K Kvols; M R Mahoney; J Rubin
Journal:  Cancer       Date:  2001-04-15       Impact factor: 6.860

2.  90Y-edotreotide for metastatic carcinoid refractory to octreotide.

Authors:  David L Bushnell; Thomas M O'Dorisio; M Sue O'Dorisio; Yusuf Menda; Rodney J Hicks; Eric Van Cutsem; Jean-Louis Baulieu; Francoise Borson-Chazot; Lowell Anthony; Al B Benson; Kjell Oberg; Ashley B Grossman; Mary Connolly; Hakim Bouterfa; Yong Li; Katherine A Kacena; Norman LaFrance; Stanislas A Pauwels
Journal:  J Clin Oncol       Date:  2010-03-01       Impact factor: 44.544

3.  Indium-111-pentetreotide prolongs survival in gastroenteropancreatic malignancies.

Authors:  Lowell B Anthony; Eugene A Woltering; Gregory D Espenan; Michele D Cronin; Tom J Maloney; Kevin E McCarthy
Journal:  Semin Nucl Med       Date:  2002-04       Impact factor: 4.446

4.  Serum peptide profiles in patients with carcinoid tumors.

Authors:  Kristine Calhoun; SuEllen Toth-Fejel; Julie Cheek; Rodney Pommier
Journal:  Am J Surg       Date:  2003-07       Impact factor: 2.565

5.  A Phase II trial of gemcitabine for metastatic neuroendocrine tumors.

Authors:  Matthew H Kulke; Haesook Kim; Jeffrey W Clark; Peter C Enzinger; Thomas J Lynch; Jeffrey A Morgan; Michele Vincitore; Ann Michelini; Charles S Fuchs
Journal:  Cancer       Date:  2004-09-01       Impact factor: 6.860

6.  Prospective, randomized, multicenter trial on the antiproliferative effect of lanreotide, interferon alfa, and their combination for therapy of metastatic neuroendocrine gastroenteropancreatic tumors--the International Lanreotide and Interferon Alfa Study Group.

Authors:  Siegbert Faiss; Ulrich-Frank Pape; Michael Böhmig; Yvonne Dörffel; Ulrich Mansmann; Werner Golder; Ernst Otto Riecken; Bertram Wiedenmann
Journal:  J Clin Oncol       Date:  2003-07-15       Impact factor: 44.544

7.  Efficacy of a chemotherapy combination for the treatment of metastatic neuroendocrine tumours.

Authors:  E Bajetta; L Ferrari; G Procopio; L Catena; E Ferrario; A Martinetti; M Di Bartolomeo; R Buzzoni; L Celio; M Vitali; E Beretta; E Seregni; E Bombardieri
Journal:  Ann Oncol       Date:  2002-04       Impact factor: 32.976

8.  Phase II clinical trial of parenteral hydroxyurea in combination with fluorouracil, interferon and filgrastim in the treatment of advanced pancreatic, gastric and neuroendocrine tumors.

Authors:  Andreas Kaubisch; Ron Kaleya; Hilda Haynes; Alla Rozenblit; Scott Wadler
Journal:  Cancer Chemother Pharmacol       Date:  2003-12-24       Impact factor: 3.333

9.  Phase II study of interferon gamma in malignant carcinoid tumors (E9292): a trial of the Eastern Cooperative Oncology Group.

Authors:  Keith Stuart; Donna E Levy; Tom Anderson; Constantine A Axiotis; Janice P Dutcher; Andrew Eisenberg; John K Erban; Al Bowen Benson III
Journal:  Invest New Drugs       Date:  2004-01       Impact factor: 3.850

10.  Randomized clinical trial of the effect of interferon alpha on survival in patients with disseminated midgut carcinoid tumours.

Authors:  L Kölby; G Persson; S Franzén; B Ahrén
Journal:  Br J Surg       Date:  2003-06       Impact factor: 6.939
View more
  4 in total

1.  Elevated Alkaline Phosphatase Prior to Transarterial Chemoembolization for Neuroendocrine Tumors Predicts Worse Outcomes.

Authors:  Jill K Onesti; Lawrence A Shirley; Neil D Saunders; Gail W Davidson; Mary E Dillhoff; Hooman Khabiri; Gregory E Guy; Joshua D Dowell; Carl R Schmidt; Manisha H Shah; Mark Bloomston
Journal:  J Gastrointest Surg       Date:  2015-10-21       Impact factor: 3.452

Review 2.  Neuroendocrine neoplasms of the gut and pancreas: new insights.

Authors:  Guido Rindi; Bertram Wiedenmann
Journal:  Nat Rev Endocrinol       Date:  2011-08-02       Impact factor: 43.330

3.  Putting the pieces together: necrolytic migratory erythema and the glucagonoma syndrome.

Authors:  Stephanie A C Halvorson; Erin Gilbert; R Samuel Hopkins; Helen Liu; Charles Lopez; Michael Chu; Marie Martin; Brett Sheppard
Journal:  J Gen Intern Med       Date:  2013-05-17       Impact factor: 5.128

4.  A case report on metastatic ileal neuroendocrine neoplasm to the breast masquerading as primary breast cancer: A diagnostic challenge and management dilemma.

Authors:  Alexandros Papalampros; Eustratia Mpaili; Demetrios Moris; Helen Sarlanis; Marina Tsoli; Evangelos Felekouras; Dimitrios T Trafalis; Michael Kontos
Journal:  Medicine (Baltimore)       Date:  2019-04       Impact factor: 1.817
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.